EP Wealth Advisors’s NovoCure NVCR Stock Holding History

EP Wealth Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$174K	Buy	11,511 +1,482	+15%	+$22.4K	﹤0.01%	1551
2026 Q1	$109K	Buy	+10,029	New	+$125K	﹤0.01%	1455
2023 Q3	–	Sell	-5,781	Closed	-$218K	–	767
2023 Q2	$218K	Buy	5,781 +86	+2%	+$5.34K	﹤0.01%	638
2023 Q1	$202K	Sell	5,695 -759	-12%	-$60.7K	﹤0.01%	578
2022 Q4	$473K	Buy	+6,454	New	+$486K	0.01%	388
2022 Q2	–	Sell	-2,551	Closed	-$211K	–	677
2022 Q1	$211K	Buy	+2,551	New	+$188K	﹤0.01%	565
2021 Q4	–	Sell	-2,555	Closed	-$297K	–	558
2021 Q3	$297K	Buy	2,555 +739	+41%	+$112K	0.01%	430
2021 Q2	$403K	Buy	1,816 +54	+3%	+$10.5K	0.01%	380
2021 Q1	$233K	Buy	+1,762	New	+$279K	0.01%	445

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

EP Wealth Advisors's NVCR Position: Q2 2026 in Review

EP Wealth Advisors increased its NovoCure (NVCR) stake by 15% in Q2 2026, buying an estimated $22.4K and bringing the position to 11,511 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #1551.

EP Wealth Advisors first reported a position in NVCR in Q1 2021 and has held it in 9 quarters since. The position peaked at $473K in Q4 2022. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

EP Wealth Advisors held 11,511 shares of NovoCure worth $174K as of Q2 2026.
EP Wealth Advisors bought 1,482 NovoCure shares in Q2 2026, an estimated $22.4K.
NovoCure made up ﹤0.01% of EP Wealth Advisors's portfolio in Q2 2026, its #1551 holding.
EP Wealth Advisors first reported a position in NovoCure in Q1 2021 and has held it in 9 quarters since.
EP Wealth Advisors's NovoCure position peaked at $473K in Q4 2022.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on EP Wealth Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.